Last reviewed · How we verify
Capecitabine+endocrine therapy
Capecitabine is a prodrug that converts to fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, combined with endocrine therapy to block estrogen receptor signaling in hormone-responsive cancers.
Capecitabine is a prodrug that converts to fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, combined with endocrine therapy to block estrogen receptor signaling in hormone-responsive cancers. Used for Hormone receptor-positive metastatic or advanced breast cancer (in combination with endocrine therapy).
At a glance
| Generic name | Capecitabine+endocrine therapy |
|---|---|
| Also known as | Experimental group |
| Sponsor | Henan Cancer Hospital |
| Drug class | Antimetabolite + endocrine therapy combination |
| Target | Thymidylate synthase (capecitabine); estrogen receptor (endocrine component) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Capecitabine is metabolized to 5-fluorouracil, which inhibits thymidylate synthase and incorporates into DNA/RNA to impair cancer cell proliferation. Endocrine therapy (likely tamoxifen, aromatase inhibitor, or fulvestrant) blocks estrogen receptor function, preventing hormone-driven growth in estrogen receptor-positive breast cancer. The combination targets both proliferation and hormone dependence.
Approved indications
- Hormone receptor-positive metastatic or advanced breast cancer (in combination with endocrine therapy)
Common side effects
- Hand-foot skin reaction
- Diarrhea
- Nausea
- Fatigue
- Stomatitis
- Myelosuppression
Key clinical trials
- Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment (PHASE3)
- A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer (PHASE2)
- A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) (PHASE3)
- Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (PHASE3)
- Metastasis-directed Therapy for Oligometastases of Breast Cancer (PHASE3)
- PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) (PHASE2)
- Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco) (PHASE2)
- Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Capecitabine+endocrine therapy CI brief — competitive landscape report
- Capecitabine+endocrine therapy updates RSS · CI watch RSS
- Henan Cancer Hospital portfolio CI